Indolent lymphoma · 6 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cyclophosphamide and Fludarabine (FC) Variant #15 | — | R 192 642 | — | ~20.6 mo | — | — | — | 3 |
Fludarabine monotherapy Variant #01 | — | R 11 691 | 28d | ~16.5 mo | ~52.9 mo | ~18 | ~R 210 435 PFS proxy · indirect | 4 |
FND Variant #01 | — | R 10 718 | 28d | — | — | — | — | — |
ProMACE-MOPP Variant #01 Partial | — | R 1 085 | 28d | — | — | — | — | — |
COPA Variant #01 | — | R 822 | 28d | — | — | — | — | — |
CVP Variant #01 | — | R 585 | 21d | — | — | — | — | — |
6 of 6 regimens shown